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Abstract: Aspirin and clopidogrel are the most commonly used antiplatelet agents in patients with coronary artery disease. The existence 
of resistance to these agents has been a controversial issue and new drugs are being developed to overcome this problem. Laboratory 
tests, which can identify resistance and correlate this with clinical outcome, are being studied in order to identify patients at risk of future 
thrombotic events. We discuss the evidence for the existence of antiplatelet resistance—both in the laboratory and in the clinical setting. 
So far, platelet aggregometry has been considered the gold standard test, but is very operator dependant, time consuming, and has shown 
little correlation with other available tests of antiplatelet resistance. We discuss the available tests of platelet function, their limitations, 
and evidence for their use. A simple, rapid, near-patient test, which is affordable and useful in the clinical (not just laboratory) setting, 
could allow risk stratification of patients and individualization of antiplatelet medication to improve outcome.
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Introduction
Platelets are the key players in pathological thrombus 
formation,  that  leads  to  myocardial  infarction, 
ischaemic  stroke,  and  peripheral  vascular  disease.
Aspirin,  the  oldest  antiplatelt  agent  has  shown  a 
significant benefit in the secondary prevention of these 
ischaemic events. Platelets can be activated through a 
number of pathways, and antiplatelet agents aim to 
block one or more of these.
Aspirin and clopidogrel are the antiplatelet agents 
most  commonly  used  in  patients  with  coronary 
artery  disease.  However,  some  patients  continue 
to  experience  thrombotic  events  despite  treatment 
with  these  agents,  and  this  phenomenon  has  been 
termed  antiplatelet  “resistance”.  The  exact  cause 
or  mechanism  that  underlies  such  resistance  is 
unknown; furthermore, the existence of “resistance” 
has been challenged and remains an issue of much 
contention.
Nevertheless,  it  has  fuelled  the  pharmaceutical 
industry to develop newer drugs, which will be able 
to “overcome this resistance”. Recent results from the 
TRITON-TIMI 381 and DISPERSE-22 studies provide 
promising results for the newcomer antiplatelet agents 
Prasugrel and AZD6140.
In  addition,  it  has  also  resulted  in  a  search  for 
a  laboratory  test  to  identify  patients  who  exhibit 
“resistance”  to  antiplatelet  medication,  in  order  to 
detect those at risk of future thrombotic events.
So far, light transmittance aggregometry has been 
considered the gold standard test of platelet function. 
However, this method is highly operator-dependent 
and has shown little correlation with other available 
tests  of  antiplatelet  resistance.  The  ideal  test 
to  assess  antiplatelet  medication  should  1)  use 
physiologically relevant agonists to induce platelet 
activation,  2)  be  easy  to  perform  (by  clinicians), 
3)  give  rapid  results  within  a  clinically-relevant 
timeframe, 4) correlate closely with clinical events, 
5) have a high sensitivity and 6) be affordable. None 
of the available techniques currently fulfils all these 
criteria.
In  this  paper,  we  present  the  clinical  evidence 
for the existence of antiplatelet resistance, describe 
the techniques used to date to identify antiplatelet 
resistance in the laboratory and their relative merits 
and shortcomings.
Mechanisms of Action of Antiplatelet 
Drugs
Aspirin
The  major  cyclooxygenase  product  in  platelets  is 
thromboxane  A2  (TxA2)  which  induces  platelet 
aggregation  and  acts  as  a  potent  vasoconstrictor. 
Aspirin blocks production of TxA2 by acetylation 
of  COX1,  the  enzyme  that  produces  the  cyclic 
endoperoxide precursor of thromboxane A2. Since 
platelets do not synthesize new proteins, the action 
of aspirin on platelet cyclooxygenase is permanent, 
lasting for the lifetime of the platelet (7–10 days) 
and repeated doses of aspirin produce a cumulative 
effect  on  platelet  function.  However,  aspirin  is 
considered a suboptimal antiplatelet agent since it 
antagonizes only one particular pathway of platelet 
activation, leaving several other important pathways 
unaffected.
Clopidogrel
Clopidogrel  is  a  thienopyridine  derivative.  It  is  a 
prodrug, oxidized by the hepatic cytochrome P450 
system to its active metabolite which irreversibly binds 
to the ADP-coupled P2Y12 receptor.3 P2Y12 inhibition 
thus  inhibits  ADP-induced  platelet  activation 
and  resultant  aggregation.  There  is  no  doubt  that 
clopidogrel is an effective antiplatelet agent, and when 
added to aspirin, significantly reduces the occurrence 
of thrombotic events.4 Importantly, no direct head-
to-head comparisons of aspirin and clopidogrel have 
been  performed  in  clinical  trials.  Instead,  trials  of 
clopidogrel have assessed its efficacy as an “add-on” 
therapy to aspirin, presumably to reduce thrombotic 
events in those patients in whom aspirin may not be 
totally preventive.
Ticlopidine
Ticlopidine is another thienopyridine that permanently 
inhibits  the  P2Y12  receptor.  It  is  a  prodrug  that 
requires  conversion  to  the  active  metabolite  by 
the hepatic cytochrome P450 enzyme. It is rapidly 
absorbed, highly bioavailable and has a prolonged 
effect. However, its unfavourable side-effect profile 
with risk of bone marrow suppression has placed it 
second position with regard to clopidogrel and led to 
the withdrawal of this drug in some countries (e.g. 
United Kingdom).Antiplatelet resistance—does it exist and how to measure it?
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Prasugrel
Prasugrel is a new oral thienopyridine derivative 
that produces more potent and irreversible P2Y12 
receptor blockade, with a rapid onset of action. Its 
active metabolite is R-138727 and it is deemed to 
be 10 times more potent than currently available 
thienopyridine derivatives. The JUMBO-TIMI 265 
study showed improved platelet inhibition, MACE 
and  reduction  in  ischemic  events  with  prasugrel 
compared to clopidogrel. Recent results from the 
TRITON-TIMI  381  study  comparing  clopidogrel 
with prasugrel in 13,608 patients has shown reduced 
interpatient  variability,  a  19%  relative  reduction 
in  the  primary  endpoint  of  MACE  (p = 0.0004), 
24% reduction in myocardial infarction and 52% 
relative  reduction  in  in-stent  restenosis  in  the 
prasugrel group. However, bleeding complications 
were also more frequent with prasugrel, especially 
intracranial  hemorrhage  in  patients  with  prior 
CVA/TIA.
AZD6140
AZD6140  is  an  oral  and  reversible  P2Y12  receptor 
blocker  that  does  not  require  hepatic  conversion 
to  an  active  metabolite  and  produces  an  overall 
superior ADP-induced  platelet  inhibition  with  less 
response variability than clopidogrel. It belongs to 
the  cyclopentyltriazolopyrimidine  group  and  has 
rapid onset and offset of action, which may make it 
particularly useful in patients who have to undergo 
imminent surgery. Results from the DISPERSE 2 study 
showed  superior  platelet  inhibition  with AZD6140 
when compared to standard dose of clopidogrel in 
990 patients with acute coronary syndromes, although 
this did not translate into a significant reduction in 
the  rates  of  myocardial  infarction.6,7  The  PLATO 
study  will  compare AZD6140  with  clopidogrel  in 
18,000  patients  with  ACS.2  AZD6140  is  still  not 
licensed for clinical use.
Cangrelor
This is a potent parenteral P2Y12 receptor antagonist. 
It is an ATP analogue with a very rapid onset and a 
short half-life, with recovery of platelet function in 
20–50 minutes after discontinuation of the drug. Its 
rapid onset of action makes it an attractive option for 
patients undergoing emergent PCI even if they then 
need to go on to have bypass surgery. The ongoing 
CHAMPION  study  is  comparing  clopidogrel  with 
cangrelor in patients undergoing PCI.6 This drug is 
still not licensed for clinical use.
Glycoprotein iib/iiia inhibitors
Glycoprotein IIb/IIIa receptors on the platelet surface 
bind fibrinogen, and are the final common pathway 
of platelet activation. The GP IIb/IIIa receptor may 
be activated by any platelet agonist and consequently 
inhibition  of  binding  to  this  receptor  blocks 
platelet aggregation induced by any agonist. Three 
agents  approved  for  use  at  present  are  abciximab, 
eptifibatide and tirofiban. All are effective but need 
to be given intravenously and are only approved for 
short-term use.
Dipyridamole
Dipyridamole  interferes  with  platelet  function 
by  increasing  the  cellular  concentration  of  cyclic 
AMP. This effect is mediated by inhibition of cyclic 
nucleotide phosphodiesterase and/or by blockade of 
available uptake of adenosine, which acts at adenosine 
A2 receptors to stimulate platelet adenylyl cyclase. 
It has little or no benefit as an antithrombotic drug. 
In  trials  in  which  a  regimen  of  dipyridamole  plus 
aspirin was compared with aspirin alone, dipyridamole 
provided  no  additional  beneficial  effect.8 A  single 
study suggests that dipyridamole plus aspirin reduces 
strokes  in  patients  with  prior  stroke  or  transient 
ischemic attack.9
Cilostazol
Cilostazol is a reversible cAMP phosphodiesterase 
inhibitor  with  antiplatelet,  antithrombotic  and 
vasodilatory  effects.  Compared  to  either  placebo 
or  pentoxifylline  in  six  double-blind  randomised 
controlled trials, it has been shown to be effective 
in reducing intermittent claudication in patients with 
peripheral arterial disease.10
BM573
BM573 is a thromboxane A2 synthase inhibitor and 
receptor  antagonist.  It  has  been  shown  to  reduce 
atherosclerosis in LDL-deficient mice, suggesting it 
may have a role to play in preventing progression of 
atheroma. It is still in development.11Saraf et al
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Laboratory Tests for Monitoring 
Antiplatelet Therapy
Platelet function tests were devised to detect patients 
with abnormal platelet reactivity, which may be inborn 
or acquired. A number of tests are currently available 
to assess platelet function, some laboratory based and 
some near patient point of care tests. They have been 
used in a number of research studies to detect the effect 
of antiplatelet medication, however none are in routine 
clinical use as the available tests demonstrate a large 
variability in the response to antiplatelet medication, 
with  variable  prevalence  of  “resistance”.  The  most 
frequently performed platelet function test is platelet or 
whole blood aggregation induced by ADP or collagen. 
Platelet aggregometry has been described as the “gold 
standard” platelet function test, against which other 
platelet function tests are compared. Flow cytometry is 
also frequently used to measure platelet activation, and 
has additional advantages over global tests of platelet 
function in providing detailed analysis of the surface 
markers on the platelet. This provides greater insight 
into the pathomechanism of platelet activation, but may 
provide less detailed information on platelet activation. 
Near patient point of care tests are more convenient 
and  provide  more  readily  available  test  results  for 
clinicians. However, the Scientific and Standardization 
Committee and the International Society on Thrombosis 
and Haemostasis do not recommend use of platelet 
function  testing  outside  research  trials,  as  there  is 
inadequate data addressing the clinical effectiveness 
of tailoring antiplatelet therapy based on laboratory 
results of antiplatelet resistance.12
Bleeding time
Dating back as far as 1901, this simple test measures 
the time it takes for a small skin cut to stop bleeding. 
It has very poor reproducibility and no study so far has 
shown it to correlate with bleeding or thrombotic risk.
Light transmittance aggregometry
Regarded  as  the  gold  standard  test  for  assessing 
platelet  reactivity  and  for  validating  other,  newer 
tests.  Baseline  light  transmittance  is  performed  on 
whole blood or platelet fraction, and compared with 
transmittance  following  the  addition  of  platelet 
agonists, such as arachidonate, ADP, thrombin receptor 
activating peptide, collagen, or epinephrine. Platelets 
clump in response to these agents and an increase in 
light transmittance is noted. Subjects whose platelet 
aggregation is more than 20% with arachidonate are 
considered aspirin resistant. It is relatively expensive, 
time consuming, performed on anticoagulated blood 
and variability in results has been reported.
Flow cytometry
Here,  blood  cells  are  labelled  with  a  fluorescently 
conjugated monoclonal antibody and are then passed 
through a flow cytometer, at 1000 to 10 000 cells per 
minute. They then pass through an active laser light, 
which activates the fluorophore that is conjugated to 
the monoclonal antibody. The intensity of fluorescence 
is directly proportional to the antigen being studied. 
P  selectin  (CD62)  is  expressed  on  the  surface  of 
activated  platelets,  and  helps  in  formation  of  the 
monocyte-platelet aggregates, which are considered 
to be the most sensitive marker of platelet activation.
Urinary thromboxane
Urinary thromboxane is a simple test to assess platelet 
activation  through  urinary  metabolites.  Activated 
platelets synthesize 11-dihydroxy thromboxane B2, an 
active metabolite of TxA2, and this is detected in urine 
with an ELISA assay. However, although detection 
of  11-dihydroxy  thromboxane  B2  in  urine  reflects 
systemic TxA2 formation, 30% is derived from non-
platelet sources and thus falsely high readings may be 
observed in inflammatory conditions.13
PFA-100
The PFA-100™ System (Dade Behring, Germany) is 
a semi-automated dual channel device. Blood is drawn 
into a tube containing 3.2% citrate and allowed to 
stand for between 30 min and 4 h, after which 800 µl 
of citrated whole blood is added to each of two pre-
prepared cartridges to wet the filters. Both cartridges 
contain  a  membrane  coated  with  type  I  equine 
collagen together with an agonist to induce platelet 
aggregation. In one cartridge the membrane is coated 
with 10 µM epinephrine and the other with 10 µM 
ADP. The measurement begins by drawing the blood 
through a capillary tube and a single aperture (150 µm 
diameter)  into  a  collagen  coated  cellulose-acetate 
filter. This results in the platelets being pre-activated 
by shear stress of 190 dynes/cm2 even before reaching 
the filters and the agonists. As platelets come into 
contact with the collagen, they adhere, aggregate and Antiplatelet resistance—does it exist and how to measure it?
Clinical Medicine: Cardiology 2009:3  81
form the primary hemostatic plug, which occludes the 
aperture (closure time, CT). The greater the platelet 
inhibition, the longer the closure time.
verify now
The Verify Now system (Accumetrics, California) is a 
platelet function assay utilizing light source to detect 
the amount of platelet aggregation. Platelets adhere to 
the fibrinogen coated beads in the tube, aggregate and 
fall out of solution, changing the extent and rate of 
light transmittance. Light transmittance is inversely 
related to the amount of platelet aggregation. There 
are 3 types of assays available. The Aspirin assay 
utilizes arachidonic acid as an agonist to assess the 
antiplatelet  effect  of  aspirin.  Similarly,  the  P2Y12 
assay utilizes ADP as an agonist to assess the effect of 
clopidogrel and the IIbIIIa assay utilizes a thrombin 
receptor activating peptide as an agonist to assess the 
response to IIbIIIa inhibitors.
TeG 5000 thromboelastograph 
haemostasis system
Thrombelastography (Haemoscope, USA) measures 
all  phases  of  haemostasis  from  clot  formation  to 
clot lysis. Blood is held in a cylindrical cup which 
oscillates  through  an  angle  of  approximately 
5  degrees. A  pin  is  suspended  into  this  blood  by 
a  torsion  wire,  and  monitored  for  motion.  The 
strength  of  the  fibrin  platelet  bond  during  clot 
formation affects the magnitude of the pin motion, 
giving an idea of overall haemostasis. TEG Platelet 
Mapping  technology  allows  estimation  of  the 
percentage  inhibition  of  platelet  aggregation  by 
aspirin,  clopidogrel  or  GPIIb/IIIa  inhibitors,  thus 
allowing tailoring of individual antiplatelet therapy.
Global Thrombosis Test (GTT)
The  Global  Thrombosis  Test  (GTT)  (Montrose 
Diagnostics  Ltd,  UK)  is  a  novel  platelet  function 
test, which is currently the most physiological test of 
platelet reactivity, in that the technique is performed 
on non-anticoagulated, native blood, without added 
external  agonists.  In  this  technique,  an  occlusive 
thrombus is formed using high shear stress, analogous 
to that in a stenosed coronary artery. This first phase of 
the test creates an occlusive thrombus under conditions 
of  high  shear  and  is  used  as  marker  of  platelet 
function, the more reactive the platelets, the faster 
the occlusion will occur (occlusion time, seconds). 
The restart of blood flow following occlusion is due to 
spontaneous thrombolysis (lysis time, seconds). This 
is a near-patient test, which provides a result within 
10 minutes on the patient’s thrombotic status, and is 
thus highly applicable to acute clinical situations, as 
well as more general screening. Studies correlating 
GTT with clinical outcomes are currently in progress 
and early results suggest it may have an important 
role in clinical practice.14
Limitations of platelet Function Tests
Most  tests  lack  sensitivity,  have  low  positive 
predictive value for clinical events and are difficult 
to perform in the clinical setting. Furthermore, most 
tests are performed on anticoagulated blood or use 
supra-high  doses  of  agonists  to  induce  platelet 
aggregation, so the physiological relevance of such 
tests remains questionable. There is clearly a need 
for a truly physiological, reliable, reproducible and 
clinically relevant test.15 Tests such as aggregometry 
and  flow-cytometry  are  time  consuming,  need 
special expertise to perform and are not applicable 
to providing a rapid result in the clinical setting to 
influence practice. A common drawback with many 
platelet  function  tests  has  been  the  lack  of  serial 
measurements. Furthermore, most studies have been 
carried out on a small number of patients and there has 
been no published study suggesting an improvement 
in  clinical  outcome  with  tailoring  of  antiplatelet 
medication based on the results of platelet function 
tests.  Recent  studies  comparing  the  results  with 
different platelet function tests noted there was wide 
variability and poor correlation amongst them.15,16
evidence that Antiplatelet Resistance 
exists
Definition of “resistance”
The  term  “resistance”  as  applied  to  antiplatelet 
medication  implies  an  endogenous  mechanism  in 
certain  individuals,  which  prevents  the  drug  from 
exerting  its  full  antithrombotic  effects.  This  is 
however,  a  misnomer. Almost  all  drugs  known  to 
man  exert  varying  effects  in  different  individuals 
and this should not be termed resistance. The causes 
for this are plentiful, and listed below. The proposed 
mechanisms  underlying  antiplatelet  resistance  to 
aspirin and clopidogrel are summarised in Table 1.Saraf et al
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From a clinical point of view, the term “resistance” 
has been used to describe the ongoing thrombotic events 
that occur in some individuals despite taking antiplatelet 
medication. However, the laboratory phenomenon of 
resistance is based on the results of platelet function 
tests, which show incomplete inhibition of aggregation 
by the medication in question. We will now discuss the 
evidence for existence of “antiplatelet resistance”.
Laboratory evidence of Antiplatelet 
Resistance
The prevalence of aspirin “resistance” is considered 
to be between 5%–60%, with a similar prevalence 
of  clopidogrel  resistance.  Studies  reporting  aspirin 
resistance are summarized in Table 2. Studies reporting 
on  the  phenomenon  of  clopidogrel  resistance  are 
summarized in Table 3. The prevalence of antiplatelet 
resistance varies with the laboratory method used, the 
drug studied, the drug dose and with the disease state. 
As shown in Tables 1 and 2, there is wide variation in 
the reported prevalence of antiplatelet resistance and 
lack of consistency between studies.
prevalence of Antiplatelet Resistance 
in Different populations17,18
Stable coronary artery disease
A  prospective  study  of  326  patients  with  stable 
CAD revealed the incidence of aspirin resistance 
Table 1. Proposed mechanisms underlying antiplatelet resistance.
Reduced Bioavailability Non compliance
inadequate dose
Poor absorption (e.g. enteric coated aspirin)
increased metabolism
interaction with drugs involving the cytochrome P-450 CYP3A4 
system (important for prodrugs converted by this system to the 
active metabolite, e.g. clopidogrel)
Drug interaction-e.g. NSAiDS, ACe inhibitors65
Genetic variation Mutation of COX1 gene
Poymorphisms in the COX1, GPia/iia, GP iiia, P2Y1 or P2Y12 genes
Polymorphism P-450 CYP3A gene (for clopidogrel and other 
prodrugs metabolised by this system)
Platelet glycoprotein receptor polymorhism
Overexpression of COX2 in platelets and endothelial cells
enhanced platelet turnover increased platelet production by the bone marrow
introducing new platelets not exposed to aspirin or clopidogrel 
(e.g. transfusion)
Cigarette smoking induced platelet activation66–68
increased erythrocyte induced platelet activation69–72
Alternate pathways of platelet activation TXA2 synthesis induced by cytokines, by oxidative stress or by 
nucleated cells
Catecholamine induced platelet activation due to excessive 
exercise and mental stress73–76
High shear stress, collagen, thrombin and other pathways of 
platelet activation
individual variation Diabetes or insulin Resistance
Hypercholesterolemia
Hypertension
elderly patients
Obesity
Sexual variationAntiplatelet resistance—does it exist and how to measure it?
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was 5.5% when assessed by LTA and 9.5% when 
assessed  using  the  PFA-100.19,20  Another  study 
of 98 subjects showed 30% resistance in patients 
on  aspirin  160 mg/d  using  the  PFA-100,21  with 
another study using the PFA-100 reporting a 27% 
incidence.22
Acute coronary syndrome
Among 104 ACS patients tested with the PFA-100, 
the incidence of aspirin resistance was found to be 
40%.22 The Warfarin Aspirin Reinfarction II Study 
(WARIS-II) study allocated 202 patients to receive 
aspirin,  warfarin  or  both.  Aspirin  resistance  was 
observed  in  35%  of  subjects  taking  aspirin  alone 
and  in  40%  taking  aspirin  and  warfarin.  Major 
adverse  cardiac  events  occurred  more  frequently 
in  aspirin  non-responders  compared  to  responders 
(36% vs. 24%, p = 0.28).23
elective PCi
The  VerifyNow  assay  was  used  to  detect  aspirin 
resistance in 151 Asian patients undergoing elective 
PCI. All patients had been taking 80–325 mg aspirin 
for at least a week prior to the procedure, yet 19% 
were found to be aspirin resistant.24
in-stent restenosis
In a study of 204 patients, 31% patients with in-stent 
restenosis were found to be aspirin resistant using 
PFA-100,  compared  to  11%  of  those  with  patent 
stents (p  0.001).25
Clinical Significance of Antiplatelet 
Resistance
The  concept  of  antiplatelet  resistance  is  variably 
defined.  It  is  not  clear  whether  the  definition  of 
antiplatelet resistance should be based on laboratory 
results or clinical outcomes. However, several recent 
studies  suggest  that  antiplatelet  therapy  resistance 
is associated with an increase in the risk of adverse 
cardiovascular outcomes in patients with CAD, CVA 
or PVD (Table 4 and Table 5).
Stable CAD
A study by Gum and co-workers (using optical platelet 
aggregation) evaluated 326 patients with stable CAD 
receiving  aspirin  for  greater  than  7  days. Aspirin-
resistance was identified if the aggregation was greater 
than 70% in response to 10 micromolar ADP or greater 
than 20% with 0.5 mg/mL of arachidonic acid. Based 
on this definition, 5.5% of patients were “resistant” and 
Table 2. Summary of laboratory tests reporting Aspirin resistance.
study n Type of subjects Aspirin dose platelet function test prevalence of resistance (%)
Gum et al50 325 Stable CAD 325 mg ADP and AA induced 
optical aggregation
5.2
Mueller et al38 100 PAD 100 mg Corrected whole blood 
aggregometry
60
Grotemeyer et al35 180 CvA 1500 mg Platelet reactivity 33
Chen et al24 151 elective PCi 80–325 mg RPFA 19
Andersen et al23 202 Post Mi 160 mg Aspirin vs. 
75 mg Apirin plus 
warfarin
PFA-100 35% in patients taking aspirin 
only, vs. 40% in patients 
taking aspirin and warfarin
Macchi et al21 98 Stable CAD 160 mg PFA-100 29%
Helgason et al51 306 CvA 300–325 mg ADP induced platelet 
aggregation
25%
Hobikoglu et al22 204 ACS: 104 Stable 
CAD: 100
80–300 mg PFA-100 40% in ACS  
27% in Stable CAD
Grundmann et al52 53 CvA/TiA in prev 
3 days 35
100 mg PFA-100 34% in symptomatic  
0% in asymptomatic patients
Alberts et al53 129 CvA 81 mg vs. 325 mg PFA-100 37% overall, with 56% in 
patients on 81 mg vs. 28% in 
those on 325 mg aspirin.Saraf et al
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had a significant increase in the combined endpoint of 
death, MI or stroke over a follow up period of nearly 
2 years, compared to responders.26
elective PCi
The VerifyNow assay was used to detect antiplatelet 
resistance  to  GPIIb/IIIa  inhibitors  in  485  patients 
undergoing  elective  PCI.  Patients  whose  platelet 
function was inhibited by 90% or more had an event 
rate  of  2%  compared  with  10%  for  patients  with 
inhibition of less than 90%.27
Holzholter  measured  platelet  reactivity  in  802 
patients  undergoing  elective  PCI  after  600  mg 
clopidogrel loading and concluded that patients with 
high platelet reactivity had a worse clinical outcome 
at 30 days.28
Primary angioplasty
Reduction in platelet aggregation in response to high 
dose loading treatment with aspirin and clopidogrel 
was assessed in 60 patients presenting with acute ST 
elevation MI undergoing primary PCI. They were 
divided into 4 quartiles based on reduction in platelet 
aggregation using the cone and plate aggregometer. 
Patients in the first quartile had platelet aggregation 
103% ± 8%, whereas those in the 2nd, 3rd and 4th 
quartile had platelet aggregation of 69, 58 and 33% 
of their respective baselines. At 6 months’ follow-
up, 7 patients in the first quartile and 1 patient in 
the 2nd quartile had experienced a cardiovascular 
event.29
Stent thrombosis
Gurbel  and  coworkers  compared  20  patients  with 
subacute  stent  thrombosis  (SAT)  to  100  patients 
undergoing PCI who did not experience SAT. Using 
LTA to assess platelet reactivity and VASP to assess 
clopidogrel effect, the results suggested that high post 
treatment platelet reactivity and incomplete inhibition 
of  P2Y12  are  risk  factors  for  stent  thrombosis.30 
In another study of 105 patients undergoing elective 
PCI, 5%–11% were identified as being clopidogrel 
Table 3. Summary of laboratory tests reporting clopidogrel resistance.
study n condition 
studied
Loading dose 
clopidogrel
Maintenance 
dose 
clopidogrel
platelet 
function test
prevalence of 
resistance
Gurbel et al54 92 PCi 300 mg 75 mg LTA 31%–35%
Angiolillo et al55 52 Diabetes 300 mg 75 mg LTA and Flow 
cytometry
38% in DM, 8%  
in non-DM
Angiolillo et al56 48 PCi 300 mg 75 mg LTA 44%
Lepantalo et al57 50 PCi 300 mg 75 mg LTA and PFA 100 40%
Jaremo et al58 18 PCi 300 mg 75 mg LTA 28%
Lev el et al59 150 PCi 300 mg – LTA 24%
Mobely et al60 50 PCi 300 mg 75 mg LTA 30%
Muller et al61 115 PCi 600 mg 75 mg LTA 5%–11%
Barragan et al62 48 iSR16  
vs  
no iSR32
Clop 75 mg B.i.D. 
vs. Ticlopidine 
250 mg B.i.D.
Flow cytometry 63% (iSR) vs. 40%  
(no iSR)
Bounamici et al32 804 iSR 600 mg 75 mg ADP induced 
platelet 
aggregation
13%
Ajzenberg et al63 32 iSR10  
vs.  
no iSR22
300 mg 75 mg Shear induced 
platelet 
aggregation 
(SiPA)
41% (cases) vs. 18% 
(controls) at shear rate 
of 200/s 57% (cases) vs. 
23% (controls) at shear 
rate of 4000/s
Matetzky et al29 60 STeMi 300 mg 75 mg LTA 25%
Dziewierz et al64 31 CAD 300 mg – LTA 23%Antiplatelet resistance—does it exist and how to measure it?
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non-responders  and  among  these  patients,  2  SATs 
were documented.31
In  a  well-conducted  large,  prospective  study, 
Bounamici  and  co-workers  measured  platelet 
aggregation  in  response  to  ADP  in  804  patients 
undergoing coronary intervention with a drug eluting 
stent and followed them up for 6 months. The incidence 
of SAT was 8.6% in nonresponders (105 patients) and 
2.3% in responders suggesting a strong correlation 
between stent thrombosis and clopidogrel resistance.32 
Another small study showed that 10 patients with 
SAT had significantly greater shear-induced platelet 
aggregation compared to PCI patients who had not 
experienced  SAT  or  compared  to  normal  controls, 
indicating  that  resistance  to  antiplatelet  therapy 
and  increased  shear  induced  platelet  aggregation 
correlated well with stent thrombosis.33
The  interval  between  SAT  and  assessment  of 
antiplatelet resistance in all the above studies was 
variable. Also,  the  patient  population  was  diverse 
hence further trials are required to assess the relation 
between stent thrombosis and antiplatelet resistance 
mechanisms.
Cerebrovascular disease
A small study compared 35 patients with symptoms 
(ischemic stroke or TIA) in the preceding 3 days to 
18  patients  without  symptoms  (no  CVA  symptom 
for 24 months), all of who had been taking aspirin 
for at least 5 months. Using the PFA-100, 34% of 
symptomatic  patients  were  identified  as  aspirin 
resistant  compared  to  none  of  the  asymptomatic 
patients.34
Among 180 stroke patients, aspirin resistance was 
identified in 33%. All patients were followed up for 
2 years and major end points were observed in 40% of 
aspirin resistant patients compared with 4% of aspirin 
responders (p  0.0001).35
Diabetes
Angiolillo and colleagues assessed platelet reactivity 
using LTA and flow cytometry in 173 type 2 diabetics 
Table 4. Summary of recent studies reporting on the clinical correlates of laboratory antiplatelet resistance to aspirin.
study population Follow-up Method primary 
endpoint
clinical implications
Gum et al26 Stable CAD 
(n = 326)
2 yrs Optical aggregometry MACe 5.2% resistance, associated 
with increased risk (hazard 
ratio 3.12) of Cv death, Mi or 
stroke
Substudy of 
HOPe77
Patients with Mi, 
stroke or Cv death 
(n = 488)
5 y Urinary thromboxane 
metabolite levels
MACe Patients in the upper quartile 
had 1.8 times higher risk 
than those in the lower 
quartile (p = 0.009)
Mueller et al78 intermittent 
claudication 
undergoing 
peripheral 
angioplasty 
(n = 100)
18 m Corrected whole 
blood aggregometry
iSR Risk of reocclusion at the 
site of angioplasty was 87% 
higher in patients with failed 
inhibition of aggregation to 
collagen and ADP
Pamukcu et al79 ACS (n = 105) 1 y PFA-100 MACe MACe occurred in 45% 
of patients with aspirin 
resistance and in 12% in 
aspirin-sensitive patients
Grotemeyer et al80 Cerebrovascular 
disease (n = 174)
2 y Platelet reactivity 
test- Residual 
number of platelets 
in supernatant of 
centrifuged samples81
MACe Recurrent stroke, Mi 
or vascular death was 
more likely to occur in 
aspirin non-responders 
compared with responders 
(40 vs. 4.4%, p  0.001)Saraf et al
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with CAD on dual antiplatelet therapy, and showed 
that patients with high platelet reactivity (HPR) had 
an increased risk of MACE with a hazard ratio of 
3.35. High platelet aggregation in diabetic patients 
may be secondary to various factors such as decreased 
nitric oxide production, increased sensitivity to ADP 
and overproduction of leptin receptors secondary to 
obesity.36 The OPTIMUS study showed HPR in 60% 
of  diabetic  patients  despite  treatment  with  150 mg 
daily  clopidogrel,  suggesting  that  high  doses  of 
clopidogrel may not overcome the increased platelet 
reactivity in certain population subgroups.37
Peripheral vascular disease
A study of 100 patients with intermittent claudication 
undergoing elective ileofemoral balloon angioplasty 
assessed  for  aspirin  resistance  using  whole  blood 
aggregometry at baseline and at regular intervals for 
up to a year post angioplasty. Reocclusion at the site 
of angioplasty during follow up occurred exclusively 
in patients who had been identified as being aspirin 
resistant.38
Management of Antiplatelet 
Resistance
The clinician is currently able to partially improve 
the responsiveness to antiplatelet therapy by acting 
on  extrinsic  factors,  involved  in  the  aetiology  of 
resistance, including compliance to treatment, drug-
drug interactions and good control of blood pressure, 
glycaemia and lipid levels. Several studies have shown 
that clopidogrel loading with 600 mg has a stronger 
and faster inhibitory effect on platelet reactivity than 
the 300 mg loading dose.39,40 Increasing the loading 
dose to 900 mg has not been shown to be of benefit, 
indicating a threshold to the platelet inhibitory effect 
of clopidogrel.41,42
The  CLEAR-PLATELETS  study  showed  that 
Clopidogrel  loading  combined  with  eptifibatide 
resulted in reduced myocardial necrosis compared to 
standard or high loading dose of clopidogrel alone.43
The  ISAR-CHOICE-2  study  demonstrated  the 
beneficial effect on platelet inhibition of increasing 
the maintenance dose of clopidogrel to 150 mg.44
In the ARMYDA-4 study, reloading with 600 mg 
clopidogel  pre  PCI  did  not  confer  any  additional 
benefit  in  patients  on  chronic  clopidogrel  therapy. 
The ARMYDA-5 study, which compared Clopidogrel 
loading with 600 mg “in lab” vs. 4–8 hours pre PCI, 
did not show any significant difference in outcome in 
the two groups, but this study was underpowered to 
detect a significant difference.45,46
Results  from  the  recent  ARMYDA-PRO  study 
suggest  high  pre  PCI  platelet  reactivity  using  the 
VerifyNow  P2Y12  assay  may  predict  MACE  at 
30 days.47 Use of point of care platelet function tests 
may help in identification of these high-risk patients, 
and assist the clinician in optimising their antiplatelet 
medications.
However, there still remains controversy over the 
benefit and the safety of high loading and maintenance 
doses of clopidogrel.
Several  studies  are  focusing  on  this  issue, 
including the CURRENT/OASIS-7 trial. This large 
population-based  study  will  evaluate  whether  high 
dose  clopidogrel  and/or  aspirin  improves  clinical 
outcome or increases bleeding risk.
Alternative antiplatelet drugs, including novel P2Y12 
ADP receptor antagonists are currently under clinical 
investigations. Results from the recent TRITON-TIMI 
38 study show that prasugrel significantly reduced 
the rates of recurrent ischemic events, including stent 
thrombosis, although this was offset by an increase in 
major bleeding.1 The GRAVITAS study is currently 
underway  to  assess  whether  tailoring  the  dose  of 
antiplatelet  medication  based  on  the  results  of  the 
VerifyNow assay improves clinical outcomes.
Whether higher doses of aspirin and/or clopidogrel 
are sufficient to overcome the “resistance” seen in 
some individuals on low doses of these drugs, is not 
known. How higher doses of aspirin and/or clopidogrel 
compare to novel antiplatelet drugs with respect to 
their antiplatelet effects and specifically, in patients 
who are “resistant” to low dose aspirin/clopidogrel 
is again, unknown. The relative bleeding risks with 
these regimens has also not been evaluated.
conclusion
There is no doubt that the laboratory phenomenon 
of  “resistance”  to  antiplatelet  medication  exists. 
There  are  many  tests  to  assess  platelet  reactivity 
and  these  have  demonstrated  a  large  variability 
in  the  response  to  antiplatelet  medication,  with 
variable prevalence of “resistance”. The definition of 
“resistance” is fraught with difficulty as the different 
methods  report  different  prevalences,  depending Saraf et al
88  Clinical Medicine: Cardiology 2009:3
on  the  test  used,  the  cut-off  value  used  to  define 
resistance, the timing with respect to medication and 
the  population  studied.  A  metanalysis  by  Hovens 
et al found heterogeneity in the prevalence of aspirin 
resistance, and this was due to the variability in results 
using different platelet function tests.48
It is extremely difficult for clinicians to determine 
which method to use to assess platelet function and 
how to interpret the results. There has been no good 
correlation  so  far  amongst  the  various  different 
platelet  function  tests.  Many  are  time  consuming, 
and not applicable to a clinical setting. None fulfils 
the  “ideal”  criteria  described  in  our  introduction. 
Furthermore,  to  date,  there  is  very  little  data  to 
suggest that altering antiplatelet medication based on 
the results of laboratory tests of “resistance” improves 
clinical outcomes.
A metanalysis by Snoep et al49 suggests patients 
with laboratory aspirin resistance are more likely to 
experience adverse cardiac events, but it is important 
to  point  out  that  no  prospective,  well-powered 
clinical  trial  has  assessed  the  benefit  of  tailoring 
antiplatelet  medication  specifically  to  populations 
with  increased  platelet  reactivity.  This  is  partly 
because  we  do  not  know  which  test  or  tests  best 
define antiplatelet resistance and which medication(s) 
best improve outcome in these patient populations. 
The approach to the problem of antiplatelet resistance 
has been to develop newer drugs to further inhibit 
platelet reactivity or increase the dose and timing of 
treatment with currently available antiplatelet agents. 
However, both these approaches have been targeted 
at “allcomers”, rather than specifically tailoring either 
of  these  approaches  to  those  patients  identified  as 
being non-responders. Importantly, the common side-
effect of bleeding with all antiplatelet medications 
means  that  the  risk  vs.  benefit  ratio  needs  to  be 
carefully balanced, and it may be more important to 
individualize such medication to subjects identified 
as “resistant” rather than giving stronger medication 
or  higher  doses  to  allcomers.  Furthermore,  the 
prevalence of “resistance” to these newly developed 
antiplatelet medications has not been evaluated.
We believe a simple, rapid, near-patient test, which is 
affordable and useful in the clinical (not just laboratory) 
setting needs to be validated in a large scale clinical trial, 
to identify patients with impaired response to antiplatelet 
medication. This  would  allow  risk  stratification  and 
individualization of antiplatelet medication to improve 
outcome  in  these  patients,  with  novel  treatments  or 
optimised doses of currently available drugs.
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